Lisdexamfetamine Dimesylate Patent Expiration
Lisdexamfetamine Dimesylate is Used for managing symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in both adults and children. It was first introduced by Takeda Pharmaceuticals Usa Inc
Lisdexamfetamine Dimesylate Patents
Given below is the list of patents protecting Lisdexamfetamine Dimesylate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Arynta | US11576878 | Oral solutions comprising lisdexamfetamine salts | Aug 30, 2040 | Azurity |
Vyvanse |
US7105486 (Pediatric) | Abuse-resistant amphetamine compounds |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7223735 (Pediatric) | Abuse resistant lysine amphetamine compounds |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7655630 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7659253 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7659254 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7662787 (Pediatric) | Abuse resistant lysine amphetamine compounds |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7662788 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7671030 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7671031 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7674774 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7678770 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7678771 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7687466 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7687467 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7700561 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7713936 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7718619 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse |
US7723305 (Pediatric) | Abuse-resistant amphetamine prodrugs |
Aug 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7105486 | Abuse-resistant amphetamine compounds |
Jun 29, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7223735 | Abuse resistant lysine amphetamine compounds |
Jun 29, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7700561 | Abuse-resistant amphetamine prodrugs |
Jun 29, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7687467 | Abuse-resistant amphetamine prodrugs |
Apr 08, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7678770 | Abuse-resistant amphetamine prodrugs |
Mar 25, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7678771 | Abuse-resistant amphetamine prodrugs |
Mar 25, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7674774 | Abuse-resistant amphetamine prodrugs |
Mar 18, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7671031 | Abuse-resistant amphetamine prodrugs |
Feb 28, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7105486 | Abuse-resistant amphetamine compounds |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7223735 | Abuse resistant lysine amphetamine compounds |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7655630 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7655630 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7659253 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7659253 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7659254 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7662787 | Abuse resistant lysine amphetamine compounds |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7662787 | Abuse resistant lysine amphetamine compounds |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7662788 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7671030 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7671031 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7674774 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7678770 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7678771 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7687466 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7687467 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7700561 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7713936 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7718619 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
Vyvanse | US7723305 | Abuse-resistant amphetamine prodrugs |
Feb 24, 2023
(Expired) | Takeda Pharms Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Lisdexamfetamine Dimesylate's patents.
Latest Legal Activities on Lisdexamfetamine Dimesylate's Patents
Given below is the list recent legal activities going on the following patents of Lisdexamfetamine Dimesylate.
Activity | Date | Patent Number |
---|---|---|
![]() | ||
Payment of Maintenance Fee, 12th Year, Large Entity | 21 Oct, 2021 | US7718619(Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 Oct, 2021 | US7713936 |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 Oct, 2021 | US7723305(Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 24 Sep, 2021 | US7700561(Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7674774(Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7687466(Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7678770(Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7671031(Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7671030(Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 18 Aug, 2021 | US7678771(Litigated) |
Lisdexamfetamine Dimesylate's Family Patents
